Key clinical point: For B-cell malignancies, synthetic lethality is a viable treatment approach, according to preliminary clinical trial data with once-daily oral DTRM-555, a triple combination therapy.

Major finding: In efficacy analysis for 22 evaluable patients, there were overall response rates of 46% in the RT group and 45% in the diffuse large B-cell lymphoma group.

Study details: The phase 1 trial in chronic lymphocytic leukemia, B-cell non-Hodgkin lymphoma, or Hodgkin lymphoma included 24 adults with life expectancy >12 weeks, good performance status and adequate organ and hematologic function.

Disclosures: Dr. Mato disclosed consultancy and research funding relationships with multiple pharmaceutical and biotechnology companies.